Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Teva reported growth for the second year in a row. Despite exceeding Wall Street targets, the company's guidance came up short. Teva reported earnings before trading began on Wednesday. The ...

2025 Free Cash Flow Guidance: $1.6 billion to $1.9 billion. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 9% increase in revenue for 2024, reaching $16.5 billion, driven by strong ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Teva Pharmaceutical reports fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion. Teva reports fourth-quarter adjusted earnings of 71 cents per share, beating ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for AVT06, Alvotech’s proposed biosimilar to Eylea ...

JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in ...

The Directorate of Enforcement (ED), Mumbai, conducted search operations at a dozen locations in the city as part of an ongoing probe against M/s Rialto Exim Pvt Ltd, M/s Pushpak Bullion Pvt Ltd ...

Portfolios of seasoned investors including Ashish Kacholia, Sunil Singhania, Ashish Dhawan, Dolly Khanna, Anil Kumar Goel and Akash Bhansali, who have parked big funds in select stocks ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone.